Safety Assessment of Ultrasound-Assisted Intravesical Chemotherapy in Normal Dogs : A Pilot Study

Sasaki, Noboru; Ikenaka, Yoshinori; Aoshima, Keisuke; Aoyagi, Teiichiro; Kudo, Nobuki; Nakamura, Kensuke; Takiguchi, Mitsuyoshi

Safety Assessment of Ultrasound-Assisted Intravesical Chemotherapy in Normal Dogs : A Pilot Study

Sasaki, Noboru; Ikenaka, Yoshinori; Aoshima, Keisuke et al.

Frontiers in pharmacology, 2022, 13, 837754

Permalink : https://hdl.handle.net/2115/85756

このアイテムのアクセス数:400件（2026-01-18 00:41 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
https://doi.org/10.3389/fphar.2022.837754			1

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	metadata only access
URI	https://hdl.handle.net/2115/85756
タイトル	Safety Assessment of Ultrasound-Assisted Intravesical Chemotherapy in Normal Dogs : A Pilot Study
著者	Sasaki, Noboru ; Ikenaka, Yoshinori ; Aoshima, Keisuke ; Aoyagi, Teiichiro ; Kudo, Nobuki ; Nakamura, Kensuke ; Takiguchi, Mitsuyoshi
e-Rad_Researcher 00754532 著者名 Sasaki, Noboru
著者名 Ikenaka, Yoshinori
著者名 Aoshima, Keisuke
著者名 Aoyagi, Teiichiro
著者名 Kudo, Nobuki
e-Rad_Researcher 80625898 著者名 Nakamura, Kensuke
e-Rad_Researcher 70261336 著者名 Takiguchi, Mitsuyoshi
言語	英語
キーワード	drug delivery
	intravesical chemotherapy
	microbubble
	non-muscle invasive bladder cancer
	pirarubicin
	ultrasound
発行日	2022-03-18
出版者	Frontiers Media
収録物名	Frontiers in pharmacology
巻(号)	13
ページ	837754
抄録	Intravesical chemotherapy after transurethral resection is a treatment option in patients with non-muscle invasive bladder cancer. The efficacy of intravesical chemotherapy is determined by the cellular uptake of intravesical drugs. Therefore, drug delivery technologies in the urinary bladder are promising tools for enhancing the efficacy of intravesical chemotherapy. Ultrasound-triggered microbubble cavitation may enhance the permeability of the urothelium, and thus may have potential as a drug delivery technology in the urinary bladder. Meanwhile, the enhanced permeability may increase systemic absorption of intravesical drugs, which may increase the adverse effects of the drug. The aim of this preliminary safety study was to assess the systemic absorption of an intravesical drug that was delivered by ultrasound-triggered microbubble cavitation in the urinary bladder of normal dogs. Pirarubicin, a derivative of doxorubicin, and an ultrasound contrast agent (Sonazoid) microbubbles were administered in the urinary bladder. Ultrasound (transmitting frequency 5 MHz; pulse duration 0.44 mu sec; pulse repetition frequency 7.7 kHz; peak negative pressure -1.2 MPa) was exposed to the bladder using a diagnostic ultrasound probe (PLT-704SBT). The combination of ultrasound and microbubbles did not increase the plasma concentration of intravesical pirarubicin. In addition, hematoxylin and eosin staining showed that the combination of ultrasound and microbubble did not cause observable damages to the urothelium. Tissue pirarubicin concentration in the sonicated region was higher than that of the non-sonicated region in two of three dogs. The results of this pilot study demonstrate the safety of the combination of intravesical pirarubicin and ultrasound-triggered microbubble cavitation, that is, ultrasound-assisted intravesical chemotherapy.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
権利情報	Creative Commons Attribution 4.0 International
EISSN	1663-9812
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.3389/fphar.2022.837754